Skip to main content
ELAB
NASDAQ Life Sciences

PMGC Holdings Subsidiary Secures Third Long-Term Aerospace & Defense Supply Agreement

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$3.42
Mkt Cap
$6.43M
52W Low
$1.62
52W High
$309.12
52W Position info
111% above low
Off High info
99% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

ELAB has more than doubled off its 52-week low of $1.62 on light trading volume (0.1× avg).

Summary

PMGC Holdings Inc.'s wholly-owned subsidiary, SVM Machining, Inc., has signed a long-term agreement to supply mission-critical aerospace and defense components, marking the third such agreement for a subsidiary this year.


Key Events · M&A and Partnerships · ELAB

  • Subsidiary Secures Long-Term Agreement

    SVM Machining, Inc., a wholly-owned subsidiary, executed a Long-Term Agreement (LTA) with Turbo-Jet Products Co., Inc. to supply mission-critical aerospace and defense components.

  • Third LTA in 2026

    This marks the third long-term agreement signed by a PMGC Holdings subsidiary in 2026, indicating a consistent trend of securing new business.

  • Strengthens Aerospace & Defense Position

    The LTA has an initial five-year term with annual renewal provisions, strengthening SVM Machining's position within the aerospace and defense supply chain and supporting U.S. government and defense-related contracts.


Analysis · ELAB · Life Sciences

This agreement, the third long-term contract secured by a subsidiary this year, is a critical operational win for PMGC Holdings Inc., especially given its recent 'going concern' warning and reliance on dilutive financing. It demonstrates the company's ability to generate revenue and strengthen its position in the mission-critical aerospace and defense supply chain, providing a positive counterpoint to recent capital raises. This consistent securing of long-term contracts is vital for the company's long-term viability and could help alleviate concerns about its financial health.

At the time of this filing, ELAB was trading at $3.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4M. The 52-week trading range was $1.62 to $309.12. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ELAB - Latest Insights

ELAB
Jul 13, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.03
Real-time Price: $0.890 info
Change: -$0.140 (-14%) info
Market Cap: $4.089M info
ELAB
Jul 07, 2026, 5:18 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.20
Real-time Price: $0.890 info
Change: -$0.310 (-26%) info
Market Cap: $4.089M info
ELAB
Jul 06, 2026, 7:32 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.33
Real-time Price: $0.890 info
Change: -$0.4387 (-33%) info
Market Cap: $4.089M info
ELAB
Jul 01, 2026, 7:33 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.57
Real-time Price: $0.890 info
Change: -$0.680 (-43%) info
Market Cap: $4.089M info
ELAB
Jul 01, 2026, 7:31 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.28
Real-time Price: $0.890 info
Change: -$0.390 (-30%) info
Market Cap: $4.089M info